Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexinidazole for rhodesiense human African trypanosomiasis
PACTR202011638938739Phase 2Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Fexinidazole in African trypanosomiasis (HAT), sponsored by Drugs for Neglected Diseases initiative. Primary endpoint: Possibly related fatality rate at the end of hospitalisation. Started Sep 2019; status: completed.
02
Drugs
Fexinidazole
03
Conditions
African trypanosomiasis (HAT)
Beyond the preview
Go deeper on PACTR202011638938739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202011638938739.